NAD+ (direct)
The molecule itself, sold direct: the least-tested route to the same blood marker.
D+
Evidence grade
D
Worth it
$40-90/month
Typical cost
DoseNo established dose exists for any outcome, because no outcome trial exists. Products commonly sell 100 to 300 mg of liposomal or sublingual NAD+; IV clinics administer gram-scale infusions over hours. Neither pattern is a studied regimen in the sense this library grades.
BasisThe precursors carry the human data (NMN C+, NR B- on this library, both for reliably raising blood NAD with no demonstrated hard outcome).
NAD+ (nicotinamide adenine dinucleotide) is the coenzyme the precursor supplements aim to raise. We grade NAD+ (direct) D+ on evidence and D for worth-it at about $40-90 per month.
What it does
NAD+ (nicotinamide adenine dinucleotide) is the coenzyme the precursor supplements aim to raise. Direct NAD+ products (oral, liposomal, sublingual, and clinic IV) skip the precursor step and sell the molecule itself. The problem is delivery: NAD+ taken by mouth is broken down during digestion into its building blocks, so an oral NAD+ capsule functions largely as an expensive precursor. Liposomal and sublingual forms claim to bypass that breakdown; the human evidence that they deliver intact NAD+ to blood or tissue in meaningful amounts is minimal.
What the research says
Raises blood NAD+ levels (the category's marker)
Evidence: weak. Established for the precursors, not for direct forms: digested oral NAD+ reaches the blood as its breakdown products, and liposomal claims rest on minimal human pharmacokinetic data rather than the repeated trial demonstration NMN and NR have.
Improves energy, cognition, or longevity outcomes
Evidence: weak. No human trial of direct NAD+ in any form has demonstrated an outcome benefit. The longevity claim inherits the premise problem in full (verification #63: whole-blood NAD does not decline with age in the seven-cohort analysis), plus a delivery problem the precursors do not have.
The precursors carry the human data (NMN C+, NR B- on this library, both for reliably raising blood NAD with no demonstrated hard outcome). Direct NAD+ has almost none: no randomized human outcome trial of oral or liposomal NAD+ exists, the pharmacokinetic support is small and largely industry-adjacent, and the oral route's digestion problem is basic pharmacology, not a controversy. IV NAD+ has a clinic literature of case series and testimonials, no controlled trials. A premium price for the least-tested delivery route grades D+.
Is it worth it?
The most expensive way to chase the category's blood marker is the route with the least human evidence behind it. At $40 to $90 a month for liposomal products (IV runs to hundreds per session), a reader who wants the marker at all gets more evidence per dollar from either graded precursor, and the outcome column is empty for the whole category. Derived from the October 2026 worth-it model.
Typical cost
$40-90/month
Common form, not a brand recommendation
Dosage context emerging
No established dose exists for any outcome, because no outcome trial exists. Products commonly sell 100 to 300 mg of liposomal or sublingual NAD+; IV clinics administer gram-scale infusions over hours. Neither pattern is a studied regimen in the sense this library grades.
Worth-it leaderboard
NAD+ (direct) sits outside the worth-it top 20.
NAD+ (direct) sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Short-term tolerability in the small studies that exist is unremarkable, but long-term human safety data for direct NAD+ products do not exist. IV administration outside trials carries clinic-setting risks the capsule does not (infusion reactions are commonly reported, and the setting is unregulated in many places). Quality varies widely in a category with no standard product. Talk to your doctor. This page is information, not medical advice.
Longevity Lab Report
NAD+ (direct) news. Graded when it happens.
The grade on this page stays free. The email carries the news on NAD+ (direct): expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-11-01
- 2026-11-01|Initial grading: direct NAD+ graded as its own record, per the 2026-10-27 shape ruling (NMN and NR keep their separate records and grades). Evidence D+: no human outcome trial exists for oral, liposomal, sublingual, or IV NAD+, the oral route is broken down in digestion, and the human data in this category belong to the precursors. Goals are empty by design: the record's only claims are a weakly supported marker claim and an unproven outcome claim, neither of which maps to a library goal at graded strength.
The week's longevity and biohacking news.
This grade for NAD+ (direct) rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.